Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine

Malaria Clinical Trial

Official title:

BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Revaccination of Young Children With BCG Vaccine.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00126217
• Other study ID #: ICA4-CT-2002-10053-REVAC
• Secondary ID: EU contract ICA4
• Status: Terminated
• Phase: Phase 4
• First received: August 2, 2005
• Last updated: October 20, 2008
• Start date: July 2002
• Est. completion date: September 2006

Study information

• Verified date: October 2008
• Source: Bandim Health Project
• Contact: n/a
• Is FDA regulated: No
• Health authority: Guinea-Bissau: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

BCG has marked immune stimulatory effects in both animal and human studies and observational studies suggest that BCG is associated with a non-specific reduction in mortality in areas with high infant and child mortality. The specific objective of the study is to examine the effect of revaccination for purified protein derivative of tuberculin (PPD) reaction, scar size, morbidity and mortality in a randomised prospective study of revaccination versus no revaccination among children 19 months of age in Guinea-Bissau. The hypothesis is that revaccination with BCG reduces childhood mortality after 19 months of age by 30%.

Description:

Examine in a randomised trial whether revaccination with BCG reduces childhood mortality after 19 months of age by 30%.

Criteria for verification: 3,000 children aged 1½ year enrolled and followed for an average of 3 years; information on potential adverse events among children with a positive PPD reaction; assessment of parasitaemia after revaccination; assessment of the tuberculin response and scar-formation after revaccination; and assessment of all-cause mortality during the period of follow-up.

Following consent to participate, children will be assessed for BCG scar and tuberculin reaction at 18-19 months of age. Subsequently, the children will be invited to a clinical examination at one of the health centres. The study will be explained again to the mother, and if she accepts to participate, she will draw a randomisation number deciding whether the child will be revaccinated or not. The BCG vaccine given will be the standard dose of 0.1 ml as recommended by WHO in this age group. In the beginning of the study, a group of 800 revaccinated and not revaccinated children will be followed weekly for two months to monitor morbidity and possible adverse effects of the vaccination. It is not expected that Koch like reactions will be common in this age group. However, should there be too many adverse reactions among children with a positive tuberculin test, only tuberculin negative children will be included in the continuation of the trial.

Two months after inclusion, the children will have another tuberculin test to examine changes in tuberculin reaction. At the same time, scar-size will be measured. In the initial phase of the project, a finger-prick blood sample will be collected from 1000 children to examine whether BCG boosting/no boosting have had an effect on the prevalence of malaria parasitaemia and the level of measles antibodies. Children with malaria will be treated and children with non-protective levels of measles antibodies will be offered revaccination with measles vaccine. In a group of children, samples will be collected both before and after BCG revaccination/no revaccination to measure changes in cytokine profile. Children with a large PPD reaction (> 15mm) will be followed in a similar way as the other children as this may reflect immune stimulation from exposure to natural TB. The studies of morbidity and immunological changes will be done both in the dry and the rainy seasons. The children will be followed for hospitalisations and mortality to 5 years of age.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2871
• Est. completion date: September 2006
• Est. primary completion date: May 2006
• Gender: Both
• Age group: 19 Months to 24 Months

Eligibility

Inclusion Criteria:

• No overt illness

Exclusion Criteria:

• PPD reaction >15mm

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Malaria

Intervention

Biological:
• Bacille Calmette Guerin (BCG)
0,1 ml, revaccination at 19 months of age

Locations

Country	Name	City	State
Guinea-Bissau	Bandim Health Project	Apartado 861, Bissau

Sponsors (4)

Lead Sponsor	Collaborator
Bandim Health Project	International Cooperation with Developing Countries, Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland, Medical Research Council Unit, The Gambia

Country where clinical trial is conducted

Guinea-Bissau, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality till 5 years of age
Primary	Hospitalisations till 5 years of age
Primary	Adverse effects within 12 months after intervention
Secondary	Tuberculin reaction 2 months after intervention
Secondary	Scar reaction 2 months after intervention
Secondary	Malaria morbidity/parasitaemia within 12 months after intervention
Secondary	Assessment of antibody and cellular immune responses 18 months after intervention